EU Probing J&J's $400M Deal For Takeda's Surgical Patch

Law360 (March 25, 2020, 4:54 PM EDT) -- Europe’s competition enforcer opened an in-depth investigation on Wednesday into Johnson & Johnson’s planned $400 million purchase of a surgical patch from Takeda Pharmaceuticals to examine concerns about the potential impact on products sold to manage bleeding.

The European Commission said in a statement that its preliminary review of the deal found that Johnson & Johnson is a leading global supplier of so-called haemostats, which are used to manage bleeding during surgeries. The review also found that Takeda’s Tachosil patch is the leading product in Europe for the most problematic bleeding situations.

Executive Vice President Margrethe Vestager, who heads up competition...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!